IRCT20190122042450N5
Recruiting
Phase 2
A Comparison between the Effect of Empagliflozin and Pioglitazon on Echocardiographic Indices in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Condition 1: Nonalcoholic fatty liver disease. Condition 2: Type 2 Diabetes. Condition 3: Cardiomyopathy.
- Sponsor
- Iran University of Medical Sciences
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Type 2 diabetes mellitus (T2DM)
- •HbA1C between 7\-10\.5%
- •Non\-alcoholic fatty liver disease (NAFLD) with cap score \>302 dB/m
- •Normal Ejection Fraction (EF\=50%)
Exclusion Criteria
- •??Arrhythmia
- •Ischemic or non Ischemic heart disease
- •Peripheral artery disease
- •Current use of SGLT2 inhibitors
- •Current use of Glucagone like peptide 1 receptor agonist
- •Current use of Thiazolidendions
- •Current use of Tamoxifen
- •Current use of Amiodarone
- •Current use of Nonsteroid anti inflammatory agents
- •Current use of Vitamin C
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90
Completed
Phase 2
Investigating the Empagliflozin effect on nonalcoholic fatty liver in patients with diabetic type 2 with metformin-containing regimensType 2 diabetic patients with nonalcoholic fatty liver disease.type 2 diabetes mellitus, nonalcoholic fatty liver disease5A11, DB92IRCT20220115053717N1Oroumia University of Medical Sciences60
Completed
Phase 2
The effect of empagliflozin on nonalcoholic fatty liver disease in diabetic patientsIRCT20190122042450N3Iran University of Medical Sciences105
Not Yet Recruiting
Phase 3
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
Recruiting
Phase 3
Empagliflozin in heart failure without diabetesHeart Failure.Heart failureIRCT20210828052313N1Shiraz University of Medical Sciences300